Search

Your search keyword '"John T. Schiller"' showing total 337 results

Search Constraints

Start Over You searched for: Author "John T. Schiller" Remove constraint Author: "John T. Schiller"
337 results on '"John T. Schiller"'

Search Results

1. Differential long-term bivalent HPV vaccine cross-protection by variants in the Costa Rica HPV vaccine trial

2. Global evaluation of lineage-specific human papillomavirus capsid antigenicity using antibodies elicited by natural infection

3. A virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in non-human primates

4. HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial

5. Harnessing Human Papillomavirus’ Natural Tropism to Target Tumors

6. Efficient Production of Papillomavirus Gene Delivery Vectors in Defined In Vitro Reactions

7. Involvement of nucleophosmin (NPM1/B23) in assembly of infectious HPV16 capsids

8. Chitosan-Poly (I:C)-PADRE Based Nanoparticles as Delivery Vehicles for Synthetic Peptide Vaccines

10. Maturation of the Human Papillomavirus 16 Capsid

11. Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047

12. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial

13. Prospects for preventing cancer with anti-microbial prophylactic vaccines

14. Comparing one dose of HPV vaccine in girls aged 9–14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial

15. Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021—March 2022

16. Supplementary Tables S1-S11 and Figure S1 from Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047

18. Data from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens

19. Data from In Vivo Longitudinal Imaging of Experimental Human Papillomavirus Infection in Mice with a Multicolor Fluorescence Mini-Endoscopy System

20. Data from Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial

22. Supplementary Video 1a from In Vivo Longitudinal Imaging of Experimental Human Papillomavirus Infection in Mice with a Multicolor Fluorescence Mini-Endoscopy System

23. Data from Reducing HPV-Associated Cancer Globally

24. Supplementary Data and Images from In Vivo Longitudinal Imaging of Experimental Human Papillomavirus Infection in Mice with a Multicolor Fluorescence Mini-Endoscopy System

25. Figures S1-S7 merged from An Infrared Dye–Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma

26. Interview with Dr. Herrero from Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica

27. Data from An Infrared Dye–Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma

28. Supplementary Video 2 from In Vivo Longitudinal Imaging of Experimental Human Papillomavirus Infection in Mice with a Multicolor Fluorescence Mini-Endoscopy System

29. Supplementary Tables 1-11 from Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica

30. Supplementary Figures and Tables from Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial

31. Recent economic evaluation of 1-dose HPV vaccination uses unsupported assumptions

32. Harnessing anti-cytomegalovirus immunity for local immunotherapy against solid tumors

33. Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial

34. Chondroitin Sulfate Proteoglycans Are De Facto Cellular Receptors for Human Papillomavirus 16 under High Serum Conditions

35. Abstract 1730: A novel chimeric virus-like drug conjugate (VDC) for the potential treatment of HPV-positive tumors

36. Comparison of Immune Responses after One Dose of HPV Vaccine in a Dose-Reduction HPV Vaccine Trial in Adolescent Girls in Tanzania to the Costa Rica Vaccine and India HPV Vaccine Trials

37. Performance of Cervical Screening a Decade Following HPV Vaccination: The Costa Rica Vaccine Trial

38. Human Papillomavirus Vaccines

39. Human papillomavirus vaccination in adults: impact, opportunities and challenges - a meeting report

40. Priming effect of bivalent and quadrivalent vaccine for HPV 31/33/45/52: an exploratory analysis from two clinical trials

41. A Prime-Pull-Amplify Vaccination Strategy To Maximize Induction of Circulating and Genital-Resident Intraepithelial CD8+ Memory T Cells

42. Efficacy of a Carrageenan gel Against Transmission of Cervical HPV (CATCH): interim analysis of a randomized, double-blind, placebo-controlled, phase 2B trial

43. HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial

44. Abstract 5331: Biological assessment of the virus-like drug conjugate AU-011 to specifically target a breadth of human cancer types

45. Continued HPV vaccination in the face of unexpected challenges: A commentary on the rationale for an extended interval two-dose schedule

46. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial

47. An Introduction to Virus Infections and Human Cancer

48. Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study

49. Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI

50. Targeting urothelial neoplasia using an investigational virus-like drug conjugate

Catalog

Books, media, physical & digital resources